Last updated: February 20, 2026
What is the Drug Identified by NDC 68180-0857?
NDC 68180-0857 corresponds to Abatacept (intravenous), marketed as Orencia IV. It is an immunomodulator used primarily to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, and other autoimmune conditions.
Market Overview
Current Market Size
The global rheumatoid arthritis treatment market reached approximately $34 billion in 2022, with biologics comprising about 70% of sales. Abatacept's specific segment for IV formulations accounts for a subset of this.
In the U.S., Orencia IV generated around $1.2 billion in revenue in 2022. Growth is driven by:
- Increasing prevalence of RA, estimated at 1.3% of adults worldwide.
- Preference shift toward targeted biologics.
- Expanded labeling for additional indications.
Competitive Landscape
Major competitors include:
- Adalimumab (Humira)
- Etanercept (Enbrel)
- Infliximab (Remicade)
- Golimumab (Simponi)
- Rituximab (Rituxan)
Orencia IV's market share is approximately 8-10% of the biologic RA market.
Patent and Exclusivity Timeline
Orencia IV was approved by the FDA in 2005. Its patent expiration for the IV formulation in key markets is projected around 2027-2028, with biologic exclusivity protections maintaining market control until then.
Pricing Landscape
Current Price Points
- Average Wholesale Price (AWP) for a single 500 mg infusion: $4,500–$5,000.
- Cost per infusion varies by dosage, administration setting, and insurance reimbursements.
Reimbursement & Cost Trends
Reimbursement policies generally cover 80–90% of the drug cost. Injectable biologics like abatacept tend to have higher reimbursement rates compared to biosimilars and smaller molecules.
Biosimilar Landscape
Biosimilar versions are in development but face market entry barriers:
- Patent litigations.
- Clinical differentiation concerns.
- Physician and patient preference for original biologics.
Expected biosimilar entry in 2027 could lower list prices by 20–40%.
Market and Price Projections
| Year |
Estimated Market Size (USD, billions) |
Projected Price Change |
| 2023 |
1.2 |
Baseline |
| 2024 |
1.3 |
+8% (inflation, demand) |
| 2025 |
1.4 |
+8% |
| 2026 |
1.5 |
+7% (pre-biosimilar) |
| 2027 |
1.6 |
Potential drop of 25% due to biosimilar competition |
| 2028 |
1.5 |
Stabilization at new low |
Revenue Drivers
- Treatment expansion to new indications.
- Increased uptake due to biosimilar entry.
- Reimbursement growth in emerging markets.
Risk Factors
- Biosimilar market penetration reducing prices.
- Regulatory delays around biosimilar approvals.
- Patent litigation extending exclusivity protections.
Key Drivers and Constraints
- Driver: Rising prevalence of RA and autoimmune diseases.
- Driver: Physician preference for branded biologics amid clinical familiarity.
- Constraint: Patent litigation delays biosimilar market entry.
- Constraint: Cost containment in healthcare systems.
Summary
Orencia IV maintains a significant position in the autoimmune biologics space with revenues around $1.2 billion in 2022. Market growth is expected to be steady through 2026 due to increasing patient needs and expanding indications. Prices are likely to fluctuate notably with biosimilar competition predicted around 2027, potentially reducing costs by up to 40%.
Key Takeaways
- The current market size for NDC 68180-0857 (Abatacept IV) is approximately $1.2 billion.
- Prices hover around $4,500–$5,000 per infusion; biosimilar competition could cut prices by almost half.
- Revenue growth is driven by treatment expansion and increasing autoimmune disease prevalence.
- Patent expiration scheduled for 2027–2028 suggests imminent biosimilar market entry, pressuring pricing.
FAQs
1. What factors could accelerate biosimilar entry for abatacept?
Patent litigation resolution, regulatory approvals, and market acceptance influence biosimilar entry speed.
2. How does the pricing of Orencia IV compare with subcutaneous formulations?
IV formulations often cost more per dose due to higher administration costs and dosing differences, with subcutaneous versions (e.g., Orencia SC) priced slightly lower or comparable.
3. How does payer coverage impact the actual patient cost?
Insurance coverage reduces out-of-pocket costs, with many payers covering 80–90%, but patient copayments vary based on formulary placement.
4. Are there upcoming approvals or new indications that could influence the market?
New indications or formulations could expand market size, but none are imminent for 2023–2024.
5. What is the likelihood of price erosion due to biosimilars?
Biosimilar entry may decrease prices by up to 40%, depending on market adoption and manufacturing scale.
References
[1] IQVIA. (2022). Global Rheumatoid Arthritis Market Report.
[2] FDA. (2005). Approval of Orencia Intravenous.
[3] Evaluate Pharma. (2022). Biologics Market Trends.
[4] U.S. Food & Drug Administration. (2023). Biosimilar Development and Approvals.
[5] Centers for Disease Control and Prevention. (2021). Autoimmune Disease Statistics.
